Adakveo

Adakveo is the brand name for crizanlizumab-tmca, a humanized monoclonal antibody that targets P-selectin, a cell adhesion molecule on activated platelets and endothelium. By inhibiting P-selectin–mediated adhesion between endothelium, leukocytes, platelets, and sickled red blood cells, Adakveo aims to reduce the frequency of vaso-occlusive crises in people with sickle cell disease.

Indications and administration: Adakveo is indicated to reduce the frequency of vaso-occlusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease. It is administered by intravenous infusion, with a dosing schedule of 5 mg/kg every four weeks after loading doses given at weeks 0 and 2. It is intended as an adjunct to standard care for sickle cell disease.

Regulatory status: Adakveo received regulatory approval from the U.S. Food and Drug Administration in 2019 for the reduction of VOC frequency in sickle cell disease. regulatory approvals may vary by region and over time.

Safety and precautions: As with other monoclonal antibodies, infusion-related reactions can occur. Reported adverse events in clinical use include symptoms such as fever, back pain, and others; serious hypersensitivity and infection risk are monitored in patients receiving the therapy. Patients are typically monitored during and after infusions.

See also: Sickle cell disease, P-selectin, monoclonal antibody therapies.